Top Breaking News | More News | Featured Stories | News By Subject | Event News | Investor News | News Archive | Search News
Get Our FREE
Industry eNewsletter
email:    

Investor News

Clinical Development News
Pre-Clinical
IND
Phase I - Safety
Phase II - Safety and Efficacy
Phase III - Controlled Safety and Efficacy
BLA/NDA/ANDA
PDUFA
Approvable Letters
Approval and Marketing Clearance
Post-Approval
Discontinued
Recalls and Warnings

Deals & Dollars News
Alliances
Earnings Reports
Financial
Investor
Mergers and Acquisitions
Start-Ups

IPO News
IPO


Clinical - Post-Approval (Research/Post Marketing/Phase IV)
Deaths Review of Eli Lilly (LLY)'s Antipsychotic Zyprexa Relprevv "Inconclusive" 3/24/2015 6:15:23 AM
Gilead (GILD) Warns After Nine Hepatitis Patients Taking Heart Drug Develop Condition, One Dies From Cardiac Arrest 3/23/2015 6:03:21 AM
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion On Application For Orphan Designation By The European Medicines Agency Agency For Ampligen To Treat Patients With Ebola Virus Disease (EVD) 3/24/2015 7:16:43 AM
Hemispherx Biopharma (HEB) To Present Data On The Activity Of Ampligen(R) Against The Ebola Virus 3/23/2015 7:38:24 AM
Merz Aesthetics (Formerly Known as BioForm Medical, Inc.) Announces Primary Endpoint Met In Post-Market Clinical Study Of Xeomin (Incobotulinumtoxina) Vs. Botox® (Onabotulinumtoxina) For Glabellar Facial Lines 3/19/2015 10:15:13 AM
Lundbeck Inc. (LUN.CO) Initiates Clinical Trial Evaluating Clobazam For Dravet Syndrome 3/17/2015 10:02:36 AM
AstraZeneca PLC (AZN)'s Brilinta Proves Worthy Despite Higher Bleeding Risk 3/16/2015 6:20:56 AM
Boehringer Ingelheim Release: Many Atrial Fibrillation Patients At High Risk Of Stroke Fail To Receive Guideline-Recommended Oral Anticoagulant Treatment 3/16/2015 9:50:44 AM
Pfizer (PFE) Pain Med Lyrica Flunks Post Market Study in Adolescents 3/13/2015 6:15:09 AM
Pfizer (PFE) Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA® Capsules CV As A Treatment For Adolescents With Fibromyalgia 3/13/2015 6:15:54 AM
Trevi Therapeutics Announces Initiation Of A Pivotal Study Of Nalbuphine ER In Prurigo Nodularis 3/11/2015 8:14:12 AM
Merck & Co. (MRK) Release: Two New Post-Hoc Analyses Of TRA 2°P TIMI 50 Study Showed ZONTIVITY (Vorapaxar) Added To Aspirin And/Or Clopidogrel Reduced Acute Limb Ischemia And Peripheral Revascularizations, Respectively, In Certain Patients With Peripheral Arterial Disease 3/5/2015 10:04:37 AM
Genentech (RHHBY)'s Breast Cancer Cocktail Buys More Than a Year of Life 2/20/2015 6:46:14 AM
Merck & Co. (MRK) Release: New Data From IMPROVE-IT Study Of VYTORIN® (Ezetimibe/Simvastatin) And TRA 2ºp TIMI 50 Study Of ZONTIVITY® (Vorapaxar) To Be Presented At American College of Cardiology Scientific Sessions 2/25/2015 11:02:59 AM
Regeneron (REGN)'s Eylea Beats Genentech (RHHBY) in Rare Face Off Over Some Vision Loss Cases 2/19/2015 6:11:14 AM
1234567
//-->